Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Valproic acid sodium salt (Sodium valproate)

Valproic acid sodium salt (Sodium valproate) (Synonyms: 2Propylvaleric Acid, Valproate, VPA)

Catalog No.GC15794

A class I HDAC inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

Valproic acid sodium salt (Sodium valproate) Chemical Structure

Cas No.: 1069-66-5

Size Price Stock Qty
10mM (in 1mL DMSO)
$38.00
In stock
5g
$58.00
In stock
10g
$92.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

IC50: 0.4 mM

Valproic acid (VPA) is a histone deacetylase inhibitor.

Histone deacetylases (HDACs), which have been recognized for their roles in controlling chromatin remodeling through histone acetylation/deacetylation, are currently known to modify a large number of non-histone proteins to regulate diverse cell processes.

In vitro: VPA showed to have cellular neuroprotective properties. In cultured neurons, VPA protected from thapsigargin-induced endoplasmic reticulum stress, glutamate-induced excitotoxicity, as well as lipopolysaccharide (LPS)-induced dopaminergic neuronal death. In midbrain neuron-glia cultures, VPA was also shown to inhibit LPS-induced, microglia-mediated inflammation [1].

In vivo: Post-pMCAO injections with VPA could decrease the brain infarct volume. Postinsult treatment with VPA also reduced the number of microglia, suppressed microglial activation, and inhibited other inflammatory markers in the ischemic brain. The reduction in acetylated histone H3 was prevented by treatment with VPA. Moreover, VPA superinduced heat-shock protein 70 and blocked pMCAO-induced down-regulation of cyclooxygenase-2. The sensory, motor, and reflex performance of pMCAO rats was improved by VPA treatment [1].

Clinical trial: In CRPC patients, VPA levels and VPA exposure duration were independent predictors for declining prostate-specific antigen (PSA). Oral VPA was not well tolerated in this patient population due to grade 1 and 2 neurologic symptoms and fatigue. Total and free VPA levels were useful for preventing severe toxicities from oral VPA. It was unlikely that PSA responses from oral VPA were related to HDAC inhibition [2].

References:
[1] Kim HJ,Rowe M,Ren M,Hong JS,Chen PS,Chuang DM.  Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther.2007 Jun;321(3):892-901. Epub 2007 Mar 19.
[2] Sharma S,Symanowski J,Wong B,Dino P,Manno P,Vogelzang N.  A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy. Transl Oncol.2008 Sep;1(3):141-7.

Reviews

Review for Valproic acid sodium salt (Sodium valproate)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Valproic acid sodium salt (Sodium valproate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.